Evidence of harm can change development decisions. We need those results as much as we need evidence of benefits. We are addressing affordability during development as well. If this work succeeds and the medicine earns FDA approval, our pricing will be comparable to that of other generic drugs. Thanks to the agreement that we've made with Mark Cuban, patients and families should understand that goal from the outset. (15:33–15:44)
STATEMENT
Asserts that if the medicine is FDA approved, its pricing will be comparable to other generic drugs.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.